HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.

Abstract
Gastric cancer remains a leading cause of cancer-related death in the world. FGF receptor 2 (FGFR2) is preferentially amplified and overexpressed in the diffuse type of gastric cancer. This review evaluates the expression and function of FGFR2 in gastric cancer, and analyzes the use of its inhibitors for gastric cancer therapy. This review also discusses the limitations of FGFR2-based therapy, and envisages future developments toward the clinical applications of FGFR2.
AuthorsLiu Hong, Yu Han, Jinqiang Liu, Lubi Brain
JournalExpert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 7 Issue 8 Pg. 759-65 (Nov 2013) ISSN: 1747-4132 [Electronic] England
PMID24134151 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • FGFR2 protein, human
  • Receptor, Fibroblast Growth Factor, Type 2
Topics
  • Animals
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Drug Resistance, Neoplasm
  • Humans
  • Molecular Targeted Therapy (adverse effects)
  • Protein Kinase Inhibitors (adverse effects, therapeutic use)
  • Receptor, Fibroblast Growth Factor, Type 2 (antagonists & inhibitors, metabolism)
  • Signal Transduction (drug effects)
  • Stomach Neoplasms (drug therapy, enzymology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: